Characterization and functional evaluation of JS207, a novel bispecific antibody against human PD-1 and VEGFA
JS207 is a promising therapeutic candidate that may address unmet clinical needs in cancer immunotherapy.
Authors
- Xiao Yi (ORCID: https://orcid.org/0000-0002-6288-5233)
- Min Eui Hong (ORCID: https://orcid.org/0000-0002-4409-4286)
- Aijuan Jia
- Jing Wang (ORCID: https://orcid.org/0000-0002-4902-7330)
- Jing Zhang (ORCID: https://orcid.org/0000-0001-8861-7336)
- Xujia Wang (ORCID: https://orcid.org/0000-0001-9907-9916)
- Yao S (ORCID: https://orcid.org/0000-0001-6769-8798)
- Lanqing Huang
- Ke Li (ORCID: https://orcid.org/0009-0003-4668-5367)
- Shihua Lin
- Qiuyun Yang
- Chun Fu Wu
- Wenting Zhao (ORCID: https://orcid.org/0000-0003-0313-5149)
Institutions
- BioReliance (United States) (US)
- Jiangsu T-mab BioPharma (China) (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1612547
- Citations
- 4
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 3.19